加州太平洋生物科学公司 PACB 深 沪
已收盘 08-29 16:00:00 美东时间
1.31
-0.020
-1.50%
华盛通- 最 高1.35
- 今 开1.34
- 成交量 326.64万股
- 最 低 1.30
- 昨 收 1.33
- 总市值 3.93亿
- 52周最高 2.72
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 0.8511
- 委 比 29.75%
- 总股本 3.00亿
- 历史最高 53.69
- 量 比 0.80
- 振 幅 3.76%
- 历史最低 0.8511
- 每 手 1
- 风险率 2.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts
Pacific Biosciences (NASDAQ:PACB) underwent analysis by 4 analysts in the last ...
08-12 02:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
PacBio And Partners Publish Benchmark Study In 'Nature Methods', Enhancing Genomic Accuracy And Reducing AI Variant Errors By 34%
PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic
08-04 21:24
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
PacBio and collaborators have developed the Platinum Pedigree dataset, a comprehensive genomic variation benchmark built using long-read sequencing and inheritance-based validation. This resource improves AI-driven variant classification, such as Google’s DeepVariant, achieving a 34% reduction in errors. The dataset includes difficult-to-sequence regions and is publicly available to advance genomics research and clinical applications.
08-04 13:05
PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications
PacBio announced the first Arab human pangenome study published in *Nature Communications*, revealing millions of previously unknown variants and 111 million base pairs of unsequenced DNA. The study, led by MBRU, assembled high-resolution genomes from 53 individuals across eight countries. This advancement improves genomic equity for underrepresented Arab populations, enhancing disease risk understanding and precision medicine. The research, powe...
07-24 13:05
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
PacBio joins the 1000 Genomes Long Read Sequencing Project, contributing Iso-Seq data from ~1,000 samples using its Kinnex RNA kits and Revio platform. This collaboration aims to enhance transcriptome insights, improve gene expression analysis, and provide a shared resource for the genetics community. Data and tools will be openly available, supporting diverse applications from basic biology to diagnostics.
07-23 13:05
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025
PacBio announced its quarterly conference call to discuss Q2 2025 financial results on August 7, 2025, at 5:00 pm ET (2:00 pm PT). The call will be webcast via PacBio’s website or accessible via toll-free and international phone numbers. PacBio is a leading life science technology company providing advanced sequencing solutions for various research applications. For more information, contact investors at ir@pacb.com or media at pr@pacb.com.
07-21 20:05
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock
Ratings for Pacific Biosciences (NASDAQ:PACB) were provided by 4 analysts in th...
06-25 22:01
Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $1.5
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $2 to $1.5.
06-25 21:56
